Ednan K Bajwa1, Uzma A Khan2, James L Januzzi3, Michelle N Gong4, B Taylor Thompson1, David C Christiani5. 1. Pulmonary and Critical Care Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 2. Department of Environmental Health, Harvard School of Public Health, Boston, MA. 3. Cardiology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 4. Pulmonary and Critical Care Division, Mount Sinai School of Medicine, New York, NY. 5. Pulmonary and Critical Care Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Department of Environmental Health, Harvard School of Public Health, Boston, MA. Electronic address: dchris@hsph.harvard.edu.
Abstract
BACKGROUND: C-reactive protein (CRP) has been studied as a marker of systemic inflammation and outcome in a number of diseases, but little is known about its characteristics in ARDS. We sought to examine plasma levels of CRP in patients with ARDS and their relationship to outcome and measures of illness severity. METHODS: We measured CRP levels in 177 patients within 48 h of disease onset and tested the association of protein level with 60-day mortality, 28-day daily organ dysfunction scores, and number of ventilator-free days. RESULTS: We found that CRP levels were significantly lower in nonsurvivors when compared with survivors (p = 0.02). Mortality rate decreased with increasing CRP decile (p = 0.02). An increasing CRP level was associated with a significantly higher probability of survival at 60 days (p = 0.005). This difference persisted after adjustment for age and severity of illness in a multivariable model (p = 0.009). Multivariable models were also used to show that patients in the group with higher CRP levels had significantly lower organ dysfunction scores (p = 0.001) and more ventilator-free days (p = 0.02). CONCLUSIONS: Increasing plasma levels of CRP within 48 h of ARDS onset are associated with improved survival, lower organ failure scores, and fewer days of mechanical ventilation. These data appear to be contrary to the established view that CRP is solely a marker of systemic inflammation.
BACKGROUND:C-reactive protein (CRP) has been studied as a marker of systemic inflammation and outcome in a number of diseases, but little is known about its characteristics in ARDS. We sought to examine plasma levels of CRP in patients with ARDS and their relationship to outcome and measures of illness severity. METHODS: We measured CRP levels in 177 patients within 48 h of disease onset and tested the association of protein level with 60-day mortality, 28-day daily organ dysfunction scores, and number of ventilator-free days. RESULTS: We found that CRP levels were significantly lower in nonsurvivors when compared with survivors (p = 0.02). Mortality rate decreased with increasing CRP decile (p = 0.02). An increasing CRP level was associated with a significantly higher probability of survival at 60 days (p = 0.005). This difference persisted after adjustment for age and severity of illness in a multivariable model (p = 0.009). Multivariable models were also used to show that patients in the group with higher CRP levels had significantly lower organ dysfunction scores (p = 0.001) and more ventilator-free days (p = 0.02). CONCLUSIONS: Increasing plasma levels of CRP within 48 h of ARDS onset are associated with improved survival, lower organ failure scores, and fewer days of mechanical ventilation. These data appear to be contrary to the established view that CRP is solely a marker of systemic inflammation.
Authors: Suzana M A Lobo; Francisco R M Lobo; Daliana Peres Bota; Flavio Lopes-Ferreira; Hosam M Soliman; Christian Mélot; Jean-Louis Vincent Journal: Chest Date: 2003-06 Impact factor: 9.410
Authors: John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason Journal: N Engl J Med Date: 2004-04-01 Impact factor: 91.245
Authors: Michelle Ng Gong; Zhou Wei; Li-Lian Xu; David P Miller; B Taylor Thompson; David C Christiani Journal: Chest Date: 2004-01 Impact factor: 9.410
Authors: M Bruijn; E M Jansen; T Klapwijk; J H van der Lee; R R van Rijn; J B M van Woensel; A P Bos Journal: Eur J Pediatr Date: 2013-05-03 Impact factor: 3.183
Authors: Benjamin Rhodes; Marilyn E Merriman; Andrew Harrison; Michael J Nissen; Malcolm Smith; Lisa Stamp; Sophia Steer; Tony R Merriman; Timothy J Vyse Journal: PLoS Med Date: 2010-09-21 Impact factor: 11.069
Authors: Pratik Sinha; Kevin L Delucchi; B Taylor Thompson; Daniel F McAuley; Michael A Matthay; Carolyn S Calfee Journal: Intensive Care Med Date: 2018-10-05 Impact factor: 17.440
Authors: Jessica J Manson; Colin Crooks; Meena Naja; Amanda Ledlie; Bethan Goulden; Trevor Liddle; Emon Khan; Puja Mehta; Lucia Martin-Gutierrez; Kirsty E Waddington; George A Robinson; Liliana Ribeiro Santos; Eve McLoughlin; Antonia Snell; Christopher Adeney; Ina Schim van der Loeff; Kenneth F Baker; Christopher J A Duncan; Aidan T Hanrath; B Clare Lendrem; Anthony De Soyza; Junjie Peng; Hajar J'Bari; Mandy Greenwood; Ellie Hawkins; Hannah Peckham; Michael Marks; Tommy Rampling; Akish Luintel; Bryan Williams; Michael Brown; Mervyn Singer; Joe West; Elizabeth C Jury; Matthew Collin; Rachel S Tattersall Journal: Lancet Rheumatol Date: 2020-08-21